Abstract | BACKGROUND AND AIMS: METHODS: We conducted a comprehensive search of several databases (inception to May 2021) to identify studies reporting on the use of EBL in the treatment of GAVE. A random-effects model was used to calculate the pooled rates; I2 values and 95% prediction intervals were calculated to assess the heterogeneity. RESULTS: Ten studies (194 patients) were included in the final analysis. The pooled rate of treatment responders with EBL in GAVE was 81% (95% confidence interval [CI], 62.2-91.7), and GAVE recurrence was 15.4% (95% CI, 4.5-41.3). The pooled mean number of treatment sessions required was 2.4 (95% CI, 2.2-2.7), and the number of bands used to achieve eradication per patient was 15.1 (95% CI, 10.7-19.4). The pooled mean difference of pre- to post-treatment hemoglobin was 1.5 (95% CI, .9-2.2; P = .001), pre- to post-treatment units of packed red blood cells transfused was 1.1 (95% CI, .4-1.9; P = .002), and pre- to post-treatment hospital length of stay was .5 days (95% CI, .1-.9; P = .01). The pooled rate of overall adverse events was 15.9% (95% CI, 10.4-23.7). CONCLUSIONS: EBL demonstrated excellent clinical outcomes in the treatment of GAVE with minimal adverse events. Multicenter randomized controlled trials comparing EBL and other modalities as initial therapy are warranted.
|
Authors | Babu P Mohan, Gregory Toy, Lena L Kassab, Suresh Ponnada, Saurabh Chandan, Sheeva Parbhu, Shaun Chandna, Douglas G Adler |
Journal | Gastrointestinal endoscopy
(Gastrointest Endosc)
Vol. 94
Issue 6
Pg. 1021-1029.e10
(12 2021)
ISSN: 1097-6779 [Electronic] United States |
PMID | 34480922
(Publication Type: Journal Article, Meta-Analysis, Systematic Review)
|
Copyright | Copyright © 2021 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved. |
Topics |
- Endoscopy
- Gastric Antral Vascular Ectasia
(surgery)
- Gastrointestinal Hemorrhage
- Humans
- Ligation
- Multicenter Studies as Topic
- Treatment Outcome
|